Sepideh Khazeni* and Bahareh Bigdeli
Freelance Research Scientist, Australia
*Corresponding Author: Sepideh Khazeni, Freelance Research Scientist, Australia.
Received: November 01, 2021; Published: December 23, 2021
Multiple myeloma (MM) is the second most common hematologic malignancy in adults, with 5-year relative survival in approximately 55.6% of patients. MM is a multifactorial disease in terms of diagnosis and treatment. The main challenge with the disease is that MM is characterized by multiple relapses and remissions with shorter remission intervals. Recently, cell therapy has improved remission in patients with relapsed or refractory MM. While avoiding vaccines that contain live viruses, COVID-19 vaccination is highly recommended for patients with MM. Here, we aim to rapidly review the literature and point out the current clinical management of MM.
Keywords: Multiple Myeloma; CAR T-Cell Therapy; Double-Hit Mm; Triple-Hit MM; COVID-19 Management
Citation: Sepideh Khazeni and Bahareh Bigdeli “Rapid Review on Multiple Myeloma; Current Clinical Management". Acta Scientific Pharmaceutical Sciences 6.1 (2022): 134-140.
Copyright: © 2022 Sepideh Khazeni and Bahareh Bigdeli. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.